The definitive benchmark for ophthalmics dealmaking
Ophthalmics partnering spans a range of chronic and vision-threatening conditions, with deal structures reflecting specialised delivery methods, targeted therapies, and distinct clinical development pathways.This report provides a comprehensive and structured analysis of 374 ophthalmics collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.
Establish a clear view of market standards
The report enables a precise understanding of how ophthalmics deals are structured in practice, allowing you to:
- Benchmark comparable transactions with confidence
- Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
- Define realistic market parameters
- Clear insight into how deal terms vary by stage, asset type, and partner profile
- Support valuation and structuring decisions with evidence
- Ground internal discussions in real transaction data rather than assumptions
- Understand how leading companies approach dealmaking
- Visibility into partner behaviour and recurring deal structures across a specialised and innovation-driven therapeutic landscape
- Full visibility into deal structure and execution
This includes:
- Rights granted and retained
- Development and commercialization responsibilities
- Financial structures and payment triggers
- Key contractual provisions and protections
Designed for real-world BD and strategy use
The report is widely used to:
- Structure and benchmark live transactions
- Prepare for negotiations with well-defined market context
- Evaluate partnership opportunities and counterparties
- Support internal strategy with robust, defensible data
What’s included?
- 374 ophthalmics collaboration and licensing deals
- Financial terms, including upfronts, milestones, and royalties where disclosed
- Fully searchable deal directory (by company, therapy, and technology)
- Direct access to SEC-filed agreements and source documents
- Analysis of deal trends, key transactions, and active dealmakers
- A trusted, evidence-based reference for ophthalmics dealmaking
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in ophthalmics dealmaking
Chapter 3 - Financial deal terms for ophthalmics partnering
Chapter 4 - Leading ophthalmics deals and dealmakers
Chapter 5 - Ophthalmics contract document directory
Chapter 6 - Ophthalmics dealmaking by therapeutic target
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio
- 4D Molecular Therapeutics
- 4P-Pharma
- A*STAR Agency for Science
- Technology and Research
- AAVnerGene
- ABB Optical Group
- Abbvie
- AbCellera Biologics
- Abeona Therapeutics
- Abpro
- ABVC BioPharma
- Accure Therapeutics
- ACE Solutech
- ActualEyes
- Acucela
- Adalvo
- Adaptive Phage Therapeutics
- Advanz Pharma
- Aequus Pharmaceuticals
- Aerie Pharmaceuticals
- AEYE Health
- AffaMed Therapeutics
- Affilogic
- AimMax Therapeutics
- AJU Pharma
- Aker BioMarine
- Alcon Laboratories
- Aldeyra Therapeutics
- Alexion Pharmaceuticals
- Alimera Sciences
- Alnylam Pharmaceuticals
- Alvotech
- Ambiopharm
- American Diabetes Association
- AmerisourceBergen
- Angios
- Apellis Pharmaceuticals
- Apexian Pharmaceuticals
- Apotex
- Applied Genetic Technologies
- Arctic Vision
- Ascidian Therapeutics
- Asimov
- Astellas Pharma
- Atsena Therapeutics
- Attillaps Holdings
- Aura Biosciences
- Aurolab
- Avanzanite Bioscience
- Avellino Labs
- Avista Therapeutics
- Axantia
- AXIM Biotechnologies
- Axovia Therapeutics
- AyoxxA Biosystems
- Bascom Palmer Eye Institute
- Bausch & Lomb
- Bausch Health Companies
- Baxter International
- Bayer
- Beacon Therapeutics
- Beam Therapeutics
- Betta Pharmaceuticals
- Beyeonics Vision
- BHVI
- Bio-Techne
- BioCryst Pharmaceuticals
- Bioeq IP
- Biogen
- BioLight
- BioStem Technologies
- Blackrock Neurotech
- Blueprint Genetics
- BlueRock Therapeutics
- Boehringer Ingelheim
- Bridge Biotherapeutics
- Brigham and Women's Hospital
- BVI Medical
- C-Bridge Capital
- California Institute for Regenerative Medicine
- Capsida Biotherapeutics
- Carl Zeiss
- Carl Zeiss Meditec
- Case Western Reserve University
- Catalent
- Catalyst Biosciences
- CDR-Life
- Celanese
- Cella Therapeutics
- Cell Cure Neurosciences
- Cellusion
- Celregen
- Cerevast Therapeutics
- Changchun High & New Technology Industries
- Character Biosciences
- Chiesi Farmaceutici
- Children's Hospital Los Angeles
- Children's Medical Research Institute
- China Grand Pharmaceutical
- China Medical System
- Choroideremia Research Foundation
- Cipla
- City Therapeutics
- Clarion Medical Technologies
- ClearPoint Neuro
- Clearside Biomedical
- Clover Therapeutics
- Coave Therapeutics
- Coherus Biosciences
- Columbia University
- Combangio
- Copernicus Therapeutics
- Cortigent
- Covenant Surgical Partners
- Cristalia
- CROMA Pharma
- CS Pharmaceuticals
- Curacle
- CureVac
- Cyagen Biosciences
- Daiichi Sankyo
- DAVI II Farmaceutica
- De La Pena Eye Clinic
- DelSiTech
- Dermira
- Diamond Pharma Services
- Diana Davis Spencer Foundation
- Digital Diagnostics
- Diopsys
- doc.ai
- DotBio
- Dr. Agarwal’s Eye Hospitals
- Dr. Reddy's Laboratories
- Duke University
- Dyno Therapeutics
- Eastman Chemical Company
- ECM Therapeutics
- Eli Lilly
- Eluminex Biosciences
- Epimune Diagnostics
- Equinox Science
- ERS Genomics
- eSight
- Eton Pharmaceuticals
- European Organization for Research and Treatment of Cancer
- Everads Therapy
- Eversight
- Evommune
- Evotec
- Exonate
- EyeCRO
- Eyedetec Medical
- Eyenovia
- EyePoint Pharmaceuticals
- Eyevensys
- Famy Life Sciences
- Fibrogen
- Find Therapeutics
- Florida Pharmaceutical Products
- Forge Biologics
- Formosa Pharmaceuticals
- Formycon
- ForSeeCon Eye Corporation
- Foundation Fighting Blindness
- FUJIFILM Cellular Dynamics
- Galimedix Therapeutics
- GC Biopharma
- GelMEDIX
- Gemini Therapeutics
- Genentech
- Genosity
- Gensci
- Gensight Biologics
- Gentex
- Glaucoma Research Foundation
- Glaukos
- Grifols
- Gyroscope Therapeutics
- Halozyme Therapeutics
- HanAll Biopharma
- HanchorBio
- Harrow Health
- Harvard Medical School
- HealPros
- Hemera Biosciences
- Hemostemix
- Henlius Biotech
- Hopstem Biotechnology
- Horama
- Horizon Discovery
- Horizon Europe
- Horizon Therapeutics
- Hovione
- I-MED Pharma
- IACTA Pharmaceuticals
- Ichor Life Sciences
- Ikarovec
- Immervision
- Immunocore
- ImPact Biotech
- Indoco
- Inflammasome Therapeutics
- InformedDNA
- InMed Pharmaceuticals
- Intas Pharmaceuticals
- Intellia Therapeutics
- Intratus
- Iolyx Therapeutics
- IQVIA
- IRIS
- IRIS International
- Israeli National Authority for Technological Innovation
- iSTAR Medical
- Itrom Pharmaceutical Group
- Ivantis
- iVeena Delivery Systems
- Iveric Bio
- Jaeb Center for Health Research Foundation
- Janssen Pharmaceuticals
- Janssen Research & Development
- jCyte
- Ji Xing Pharmaceuticals
- Johns Hopkins University
- Johnson & Johnson Vision
- Joslin Diabetes Center
- K2M
- Kanaph Therapeutics
- Kane Biotech
- Kemwell BioPharma
- Kiora Pharmaceuticals
- Kissei Pharmaceutical
- Klinge Biopharma
- Kodiak Sciences
- Konkuk University
- Kowa
- Kriya Therapeutics
- Kubota Vision
- Kuria Therapeutics
- Kwangdong Pharmaceutical
- Laboratoires Thea
- LABORATORIOS SAVAL
- Lansheng Medical
- Lantheus Holding
- Launch Therapeutics
- Lee's Pharmaceutical
- Leiden University
- LENZ Therapeutics
- LGC
- LianBio
- Lineage Cell Therapeutics
- LION Eye Group
- LLamasoft
- Lochan
- Locus Biosciences
- Lotus Pharmaceuticals
- LumiThera
- Lunatus
- Maastricht University
- Magruder Eye Institute
- Mannin Research
- Marchon Eyewear
- Massachusetts Eye and Ear Infirmary
- Mawson Infrastructure
- Max-Planck
- Mayo Clinic
- McMaster University
- mCureX Therapeutics
- Medical Food Solutions Research
- Medical University of South Carolina
- Medvisis
- MeiraGTx
- MellingMedical
- Melt Pharmaceuticals
- Menicon
- Minnetronix
- miRagen Therapeutics
- MitoChem Therapeutics
- Mitsubishi Tanabe Pharma
- Mosaic Biosciences
- Mundipharma
- MyMD Pharmaceuticals
- Nanomerics
- Nanoscope Therapeutics
- Narayana Nethralaya Foundation
- NASA
- National Cancer Institute
- National Eye Institute
- National Institutes of Health
- National Organization for Rare Disorders
- National University of Singapore
- Neuraly
- Neurolens
- Neurophth Therapeutics
- Nevakar
- NextPharma
- NGM Biopharmaceuticals
- Nicox
- Nippon Shinyaku
- Nona Biosciences
- Northway Biotechpharma
- NovaBay Pharmaceuticals
- Novaliq
- Novartis
- Novelty Nobility
- Noveome Biotherapeutics
- Novotech
- NTC
- Numab
- Ocugen
- Ocular Therapeutics
- Ocular Therapeutix
- Oculis
- Oculogenex
- Ocumension Therapeutics
- Ocuphire Pharma
- Odylia Therapeutics
- OKKO Health
- OKYO Pharma
- OliX Pharmaceuticals
- Olympic Ophthalmics
- Omega Therapeutics
- Omeros
- ONL Therapeutics
- OphtAI
- Ophthotech
- Opsis Therapeutics
- Opthea
- Optifye Therapeutics
- Optina Diagnostics
- Optomed
- Opus Genetics
- Ora
- Orbis
- Orbit Biomedical
- Osmotica Pharmaceuticals
- Otsuka
- Outlook Therapeutics
- Oxford BioMedica
- Oyster Point Pharma
- Palatin Technologies
- PanOptica
- Perelman School of Medicine
- PharmAbcine
- Pharmaleads
- Phillips-Medisize
- Pieris Pharmaceuticals
- Pierre Fabre
- Ping An Ventures
- Plex Pharmaceuticals
- Polifarma
- PolyPhotonix
- PreCerv
- Precise Biometrics
- Precision Optics
- Prevail InfoWorks
- Promedica International
- ProQR Therapeutics
- ProtoKinetix
- Provectus Biopharmaceuticals
- PTC Therapeutics
- Q BioMed
- Quest Diagnostics
- Quotient
- Rallybio
- Rayner Surgical
- Ray Therapeutics
- Re-Vana Therapeutics
- RecensMedical
- Regeneron Pharmaceuticals
- Regenerx
- Regenxbio
- RemeGen
- Remidio Innovative Solutions
- Rentschler Biotechnologie
- Resilience
- Retinagenix
- RetinAI Medical
- RetinalGeniX Technologies
- RetiSpec
- ReVision Optics
- Revision Skincare
- Revolo Biotherapeutics
- RevOpsis Therapeutics
- Ribomic
- Ripple Therapeutics
- Roche
- RTW Investments
- RVL Pharmaceuticals
- RxCell
- Rxilient Biotech
- Saban Research Institute of Children's Hospital Los Angeles
- SAMIL Pharmiceuticals
- Samsara Vision
- Samsung Bioepis
- Samsung Biologics
- SanBio
- Sanofi
- Santen
- Santen Pharmaceutical
- Santhera Pharmaceuticals
- SATT Conectus Alsace
- Schepens Eye Research Institute
- Scohia Pharma
- Second Sight Medical
- Seer
- Selagine
- SemaThera
- Senju Pharmaceutical
- Senti Biosciences
- SGN Nanopharma
- Shandong Boan Biological Technology
- Shape Therapeutics
- SIFI (Societa Industria Farmaceutica Italiana)
- Sight Sciences
- Singapore Eye Research Institute (SERI)
- Sintetica
- SipNose
- SiSaf
- Skye Bioscience
- Slayback Pharma
- Societal CDMO
- Sonoma Pharmaceuticals
- SparingVision
- Spark Therapeutics
- SpliceBio
- STADA Arzneimittel
- Stanford University
- Stanford University School of Medicine
- State University of New York
- StemSight
- Stuart Therapeutics
- Sun Pharma Advanced Research Company
- Sun Pharmaceutical
- Surrozen
- SwissLens
- Sydnexis
- Tabuk Pharmaceuticals
- Taiwan Liposome Company
- TALLC
- Tangible Science
- Taro Pharmaceuticals
- Tarsius Pharma
- Tarsus Pharmaceuticals
- TeamedOn International
- TearLab
- Technological University Dublin
- Teva Pharmaceutical Industries
- Thea Open Innovation
- ThinkCyte
- Tianjin CanSino Biotechnology
- Titan Pharmaceuticals
- Toolgen
- Topcon
- Translational Research Institute for Space Health
- Trethera
- Tufts Medical Center
- Tufts University
- Turn Biotechnologies
- UCB
- Undisclosed Company
- Uni-Bio Science
- University of British Columbia
- University of California Los Angeles
- University of Colorado
- University of Florida Research Foundation
- University of Hong Kong
- University of Massachusetts Medical School
- University of Miami
- University of Minnesota
- University of Nebraska
- University of Pennsylvania
- University of Pennsylvania School of Veterinary Medicine
- University of Pittsburgh
- Usher Syndrome Coalition
- ValenzaBio
- Verana Health
- Versea Ophthalmics
- Vial
- Viatris
- Viela Bio
- ViGeneron
- Viralgen
- Viridian Therapeutics
- Vision Care Group
- Vision Essence
- Vision Institute
- VisionWeb
- Visiox Pharma
- Visus Therapeutics
- Vivani Medical
- VivaVision Biotech
- Vivior
- Vizient
- VSP Optics
- Vyluma
- Wagner Macula Retina Center
- Wakamoto Pharmaceutical
- Wake Forest University
- Wallace H. Coulter Foundation
- WuXi Advanced Therapies
- Xbrane Biopharma
- Xencor
- Xequel Bio
- XERIS Pharmaceuticals
- Yangtze River Pharmaceutical Group
- Yarrow Bioscience
- Ypsomed
- Zhaoke (Hong Kong) Ophthalmology Pharmaceutical
- Zhonglan Electronic Technology
- ZipBio
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
